Hepatitis C virus in India: Challenges and Successes.
作者信息
Anand Abhinav
机构信息
Department of Gastroenterology and Human Nutrition Unit All India Institute of Medical Sciences New Delhi India.
出版信息
Clin Liver Dis (Hoboken). 2021 Jul 22;18(3):150-154. doi: 10.1002/cld.1137. eCollection 2021 Sep.
Abstract
摘要
相似文献
1
Hepatitis C virus in India: Challenges and Successes.
Clin Liver Dis (Hoboken). 2021 Jul 22;18(3):150-154. doi: 10.1002/cld.1137. eCollection 2021 Sep.
2
Chronic Hepatitis B: Challenges and Successes in India.
Clin Liver Dis (Hoboken). 2021 Oct 15;18(3):111-116. doi: 10.1002/cld.1125. eCollection 2021 Sep.
3
Chronic hepatitis in a large Indian hospital.
Natl Med J India. 1993 Sep-Oct;6(5):202-6.
4
Viral hepatitis in India.
Clin Lab Med. 2012 Jun;32(2):159-74. doi: 10.1016/j.cll.2012.03.003. Epub 2012 Apr 19.
5
Presence of TT virus infection in chronic hepatitis patients from a hospital in New Delhi, India.
Indian J Med Res. 2005 Jul;122(1):29-33.
6
Prevalence of hepatitis E virus infection in West Bengal, India: a hospital-based study.
J Med Microbiol. 2014 Jul;63(Pt 7):975-980. doi: 10.1099/jmm.0.072249-0. Epub 2014 May 12.
7
Epidemiology of hepatitis B virus infection in India.
Gut. 1996;38 Suppl 2(Suppl 2):S56-9. doi: 10.1136/gut.38.suppl_2.s56.
8
Transfusion-transmitted virus in association with hepatitis A-E viral infections in various forms of liver diseases in India.
World J Gastroenterol. 2006 Apr 21;12(15):2432-6. doi: 10.3748/wjg.v12.i15.2432.
9
Vaccination for hepatitis A virus is not required for patients with chronic liver disease in India.
Natl Med J India. 2002 Sep-Oct;15(5):267-8.
10
Human immunodeficiency virus, hepatitis B virus and hepatitis C virus seroprevalence in critically ill emergency department patients at a Trauma Care Centre, India.
Indian J Med Microbiol. 2016 Apr-Jun;34(2):183-5. doi: 10.4103/0255-0857.180281.
引用本文的文献
1
Risk Factors Contributing to Hepatitis C Virus Infection in Kashmir: A Meta-Analysis.
Cureus. 2025 Jun 5;17(6):e85382. doi: 10.7759/cureus.85382. eCollection 2025 Jun.
2
Impact of hepatitis C virus genotype on the efficacy of the direct-acting antivirals in chronic kidney disease patients in West Bengal, India.
BMC Infect Dis. 2025 May 16;25(1):706. doi: 10.1186/s12879-025-10947-x.
3
Sustained virological response in HCV patients receiving antiviral treatment at a teaching centre of northern India.
J Family Med Prim Care. 2025 Mar;14(3):942-946. doi: 10.4103/jfmpc.jfmpc_1379_24. Epub 2025 Mar 25.
4
Efficacy of Different Combinations of Direct-Acting Antivirals Against Different Hepatitis C Virus-Infected Population Groups: An Experience in Tertiary Care Hospitals in West Bengal, India.
Viruses. 2025 Feb 16;17(2):269. doi: 10.3390/v17020269.
5
Seroprevalence of HIV, HCV, and HBV: The Associated Psychiatric Co-morbidities Among Injection Drug Users in Kashmir- A Hospital-Based Cross-sectional Study.
Indian J Psychol Med. 2024 Jun 16:02537176241257673. doi: 10.1177/02537176241257673.
6
Who to Screen for Hepatitis C: That is the Question.
J Clin Exp Hepatol. 2022 Nov-Dec;12(6):1406-1407. doi: 10.1016/j.jceh.2022.10.004. Epub 2022 Oct 27.
本文引用的文献
1
Impact of COVID-19 on global HCV elimination efforts.
J Hepatol. 2021 Jan;74(1):31-36. doi: 10.1016/j.jhep.2020.07.042. Epub 2020 Aug 7.
2
Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: A systematic review with meta-analysis.
PLoS One. 2020 Feb 21;15(2):e0229143. doi: 10.1371/journal.pone.0229143. eCollection 2020.
3
Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs: A cluster-randomized trial.
J Hepatol. 2020 Jan;72(1):67-74. doi: 10.1016/j.jhep.2019.09.022. Epub 2019 Oct 8.
4
Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil.
Ann Hepatol. 2019 Nov-Dec;18(6):849-854. doi: 10.1016/j.aohep.2019.08.001. Epub 2019 Aug 30.
5
Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting.
J Hepatol. 2019 Dec;71(6):1076-1085. doi: 10.1016/j.jhep.2019.07.006. Epub 2019 Jul 17.
6
Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India.
Hepatol Int. 2019 Mar;13(2):173-179. doi: 10.1007/s12072-019-09927-6. Epub 2019 Feb 21.
7
Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial.
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):119-126. doi: 10.1016/S2468-1253(18)30382-0. Epub 2018 Dec 11.
8
Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C.
Interdiscip Perspect Infect Dis. 2018 Oct 1;2018:9124604. doi: 10.1155/2018/9124604. eCollection 2018.
9
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data.
J Microbiol Immunol Infect. 2020 Aug;53(4):569-577. doi: 10.1016/j.jmii.2018.09.005. Epub 2018 Sep 26.
10
Burden of hepatitis C virus infection in India: A systematic review and meta-analysis.
J Gastroenterol Hepatol. 2019 Feb;34(2):321-329. doi: 10.1111/jgh.14466. Epub 2018 Sep 26.
Zotero 插件